Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.
Richard S P HuangDavid P CarboneGerald LiAlexa SchrockRyon P GrafLiangliang ZhangKarthikeyan MurugesanJeffrey S RossKhaled TolbaJacob SandsGeoffrey R OxnardDavid SpigelPublished in: Journal for immunotherapy of cancer (2023)
This study provides evidence that higher TMB cut-offs, such as 20 muts/Mb, can identify patients with prolonged benefit from ICPI. TMB ≥20 muts/Mb is a potential biomarker that may identify patients in whom an ICPI without chemo could be considered, even in the setting of lower PD-L1 levels. Prospective validation of these findings could increase access to chemo-sparing regimens for the first-line treatment of advanced NSCLC.
Keyphrases
- small cell lung cancer
- end stage renal disease
- newly diagnosed
- photodynamic therapy
- ejection fraction
- advanced non small cell lung cancer
- chronic kidney disease
- cancer therapy
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- type diabetes
- metabolic syndrome
- robot assisted
- radiation therapy
- drug delivery
- patient reported
- minimally invasive
- tyrosine kinase
- glycemic control